Ken Griffin Ocular Therapeutix, Inc Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 33,900 shares of OCUL stock, worth $226,113. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,900

Previous 43,100 21.35%

Holding current value

$226,113

Previous $192,000 60.42%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.85 - $10.93 $7.26 Million - $20.6 Million	1,884,592 Added 53.3%	5,420,601 $49.3 Million
Q4 2023 Feb 14, 2024	BUY	$2.08 - $4.52 $4.67 Million - $10.2 Million	2,246,653 Added 174.25%	3,536,009 $15.8 Million
Q3 2023 Nov 14, 2023	BUY	$3.14 - $5.04 $124,359 - $199,609	39,605 Added 3.17%	1,289,356 $4.05 Million
Q2 2023 Aug 14, 2023	SELL	$4.6 - $7.64 $1.27 Million - $2.11 Million	-276,521 Reduced 18.12%	1,249,751 $6.45 Million
Q1 2023 May 15, 2023	SELL	$2.79 - $6.27 $1.18 Million - $2.64 Million	-421,464 Reduced 21.64%	1,526,272 $8.04 Million

Q4 2022 Feb 14, 2023	BUY	$2.61 - $4.41 $1.45 Million - $2.45 Million	555,311 Added 39.88%	1,947,736 $5.47 Million
Q3 2022 Nov 14, 2022	SELL	$4.09 - $6.5 $1.36 Million - $2.16 Million	-331,568 Reduced 19.23%	1,392,425 $5.78 Million
Q2 2022 Aug 15, 2022	BUY	$3.01 - $5.22 $95,287 - $165,249	31,657 Added 1.87%	1,723,993 $6.93 Million
Q1 2022 May 16, 2022	BUY	$4.83 - $7.35 $779,146 - $1.19 Million	161,314 Added 10.54%	1,692,336 $8.38 Million
Q4 2021 Feb 14, 2022	BUY	$6.16 - $12.07 $9.16 Million - $18 Million	1,487,417 Added 3411.12%	1,531,022 $10.7 Million
Q3 2021 Nov 15, 2021	SELL	$9.7 - $14.34 $1.05 Million - $1.56 Million	-108,645 Reduced 71.36%	43,605 $436,000
Q2 2021 Aug 16, 2021	BUY	$13.43 - $19.16 $593,189 - $846,278	44,169 Added 40.87%	152,250 $2.16 Million
Q1 2021 May 17, 2021	SELL	$15.82 - $22.11 $23.4 Million - $32.7 Million	-1,480,793 Reduced 93.2%	108,081 $1.77 Million
Q4 2020 Feb 16, 2021	SELL	$7.91 - $22.95 $261,733 - $759,392	-33,089 Reduced 2.04%	1,588,874 $32.9 Million
Q3 2020 Nov 16, 2020	BUY	$7.36 - $9.87 $10.3 Million - $13.8 Million	1,401,694 Added 636.36%	1,621,963 $12.3 Million
Q2 2020 Aug 14, 2020	BUY	$4.67 - $8.95 $752,019 - $1.44 Million	161,032 Added 271.84%	220,269 $1.84 Million
Q1 2020 May 15, 2020	BUY	$3.95 - $7.4 $108,269 - $202,834	27,410 Added 86.12%	59,237 $294,000
Q4 2019 Feb 14, 2020	BUY	$2.57 - $4.73 $34,882 - $64,200	13,573 Added 74.36%	31,827 $126,000
Q3 2019 Nov 14, 2019	SELL	$3.04 - $5.32 $5,976 - $10,459	-1,966 Reduced 9.72%	18,254 $55,000
Q2 2019 Aug 14, 2019	SELL	$2.46 - $4.52 $14,474 - $26,595	-5,884 Reduced 22.54%	20,220 $89,000
Q1 2019 May 15, 2019	SELL	$3.51 - $4.77 $135,493 - $184,131	-38,602 Reduced 59.66%	26,104 $0
Q4 2018 Feb 14, 2019	BUY	$3.87 - $7.11 $154,567 - $283,973	39,940 Added 161.27%	64,706 $257,000
Q3 2018 Nov 13, 2018	BUY	$5.42 - $6.99 $23,468 - $30,266	4,330 Added 21.19%	24,766 $0
Q2 2018 Aug 10, 2018	BUY	$5.99 - $8.17 $52,993 - $72,279	8,847 Added 76.34%	20,436 $0
Q4 2017 Feb 09, 2018	BUY	$3.73 - $6.37 $43,226 - $73,821	11,589	11,589 $52,000

Others Institutions Holding OCUL

# of Institutions

148

Shares Held

123M

Call Options Held

185K

Put Options Held

507K

View Full List

About OCULAR THERAPEUTIX, INC

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $513M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

More about OCUL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account